Ram Dharma, Rajappa Suhas K, Rawal Sudhir, Singh Amitabh, Singh Prem B, Dewan Ajay K
Department of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India.
Department of Uro-oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India.
J Minim Access Surg. 2018 Oct-Dec;14(4):298-303. doi: 10.4103/jmas.JMAS_150_17.
Open radical cystectomy (ORC) has been the standard treatment for muscle-invasive bladder cancer, but this is associated with significant morbidity and mortality. Robot-assisted radical cystectomy (RARC) has been proposed as minimally invasive alternative with improved morbidity and acceptable oncological outcomes, but a large series featuring RARC and their comparison with ORC is still lacking in India despite more than a decade of its inception. We have conducted this study with an objective to see the feasibility of RARC in the Indian context and compare it with contemporary standard.
This is a prospective cohort study conducted at two tertiary cancer institutes. We have evaluated the patients pertaining to operative and early post-operative factors from January 2014 to December 2015. Necessary statistical tests applied to see comparability of the arms and their outcomes.
A total of 170 patients underwent surgery for carcinoma bladder (45 ORC while 125 RARC). Intraoperative blood loss (RARC and ORC: 228 and 529 ml) and average transfusion rate were lower with RARC. A trend towards benefit was noted in favour of robotic arm in terms of mean complication rate (RARC and ORC: 54 and 39%).
The present study has shown comparable surgical and early post-operative outcomes with clear advantage of robotic approach in terms of intraoperative blood transfusion and lymph node yield. Although the study was non-randomised in nature, it should provide substantial evidence on safety and feasibility of RARC in the Indian context and a reference point of evidence to look ahead.
开放性根治性膀胱切除术(ORC)一直是肌层浸润性膀胱癌的标准治疗方法,但它会带来较高的发病率和死亡率。机器人辅助根治性膀胱切除术(RARC)已被提出作为一种微创替代方案,具有较低的发病率和可接受的肿瘤学结果。然而,尽管RARC已经出现了十多年,但在印度仍缺乏关于RARC及其与ORC比较的大型系列研究。我们开展这项研究的目的是了解RARC在印度背景下的可行性,并将其与当代标准进行比较。
这是一项在两家三级癌症研究所进行的前瞻性队列研究。我们评估了2014年1月至2015年12月期间患者的手术及术后早期相关因素。应用必要的统计检验来观察两组的可比性及其结果。
共有170例膀胱癌患者接受了手术(45例行ORC,125例行RARC)。RARC组术中失血量(RARC和ORC分别为228毫升和529毫升)和平均输血率较低。在平均并发症发生率方面(RARC和ORC分别为54%和39%),机器人手术组有更优的趋势。
本研究显示了可比的手术及术后早期结果,机器人手术方法在术中输血和淋巴结获取方面具有明显优势。尽管该研究本质上是非随机的,但它应能为RARC在印度背景下的安全性和可行性提供大量证据,并为未来提供一个参考依据。